[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feqXOR8cGkSWCxeGQKvTSJltoDmLLVvU1-R1tTuY7H5Q":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Holland Bloorview Kids Rehabilitation Hospital",[4],63,false,11,1,3662,2,53,[14,17,19,22,24,26,29,31],{"name":15,"count":16},"Autism Spectrum Disorder",20,{"name":18,"count":16},"Cerebral Palsy",{"name":20,"count":21},"Acquired Brain Injury",4,{"name":23,"count":21},"Stroke",{"name":25,"count":21},"Hemiplegic Cerebral Palsy",{"name":27,"count":28},"Mild Traumatic Brain Injury",3,{"name":30,"count":28},"Cerebral Palsy (CP)",{"name":32,"count":28},"Spina Bifida",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06081348","Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders","2026-09","Sertraline",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04041713","A Pilot Study of an Antioxidant Cocktail vs. Placebo in the Treatment of Children and Adolescents With Rett Syndrome","2026-11-30","Rett-T",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,90,112,148,182,206,229,253],{"intervention":38,"totalTrials":9,"cells":53},{"EARLY_PHASE1":54,"PHASE1":57,"PHASE2":59,"PHASE3":84,"PHASE4":86,"NA":88},{"trials":55,"activeCount":56},[],0,{"trials":58,"activeCount":56},[],{"trials":60,"activeCount":9,"soonestReadout":37},[61],{"nctId":35,"briefTitle":36,"status":62,"phases":63,"primaryCompletion":37,"completion":37,"start":64,"enrollment":65,"conditions":66,"interventions":83},"RECRUITING",[47],"2024-09-16",130,[67,68,15,69,70,71,72,73,74,75,76,77,78,79,80,81,82],"Neurodevelopmental Disorders","Autism","Fragile X Syndrome","Tuberous Sclerosis","22Q11 Deletion Syndrome","22Q11 Deletion","ADHD","Tic Disorders","Tourette Syndrome","Tourette Syndrome in Children","Tourette Syndrome in Adolescence","ADHD - Combined Type","ADHD Predominantly Inattentive Type","ADHD, Predominantly Hyperactive - Impulsive","Anxiety","Anxiety Disorders",[38],{"trials":85,"activeCount":56},[],{"trials":87,"activeCount":56},[],{"trials":89,"activeCount":56},[],{"intervention":43,"totalTrials":9,"cells":91},{"EARLY_PHASE1":92,"PHASE1":94,"PHASE2":96,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":93,"activeCount":56},[],{"trials":95,"activeCount":56},[],{"trials":97,"activeCount":9,"soonestReadout":42},[98],{"nctId":40,"briefTitle":41,"status":99,"phases":100,"primaryCompletion":42,"completion":42,"start":101,"enrollment":102,"conditions":103,"interventions":105},"NOT_YET_RECRUITING",[47],"2025-10-01",35,[104],"Rett Syndrome",[43],{"trials":107,"activeCount":56},[],{"trials":109,"activeCount":56},[],{"trials":111,"activeCount":56},[],{"intervention":113,"totalTrials":11,"cells":114},"Metformin",{"EARLY_PHASE1":115,"PHASE1":117,"PHASE2":119,"PHASE3":131,"PHASE4":144,"NA":146},{"trials":116,"activeCount":56},[],{"trials":118,"activeCount":56},[],{"trials":120,"activeCount":56},[121],{"nctId":122,"briefTitle":123,"status":124,"phases":125,"primaryCompletion":126,"completion":127,"start":128,"enrollment":28,"conditions":129,"interventions":130},"NCT03710343","Metformin for Motor and Cognitive Improvement in Children With Cerebral Palsy: A Feasibility Study","COMPLETED",[47],"2025-04-11","2025-04-24","2023-11-14",[18],[113],{"trials":132,"activeCount":56},[133],{"nctId":134,"briefTitle":135,"status":124,"phases":136,"primaryCompletion":137,"completion":138,"start":139,"enrollment":140,"conditions":141,"interventions":143},"NCT01825798","Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)",[48],"2015-06","2015-10","2013-04",60,[142,15],"Overweight",[113],{"trials":145,"activeCount":56},[],{"trials":147,"activeCount":56},[],{"intervention":149,"totalTrials":11,"cells":150},"Intranasal Oxytocin",{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":176,"PHASE4":178,"NA":180},{"trials":152,"activeCount":56},[],{"trials":154,"activeCount":56},[],{"trials":156,"activeCount":56},[157,166],{"nctId":158,"briefTitle":159,"status":124,"phases":160,"primaryCompletion":161,"completion":162,"start":163,"enrollment":140,"conditions":164,"interventions":165},"NCT01908205","Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)",[47],"2015-09","2016-03","2013-09",[15],[149],{"nctId":167,"briefTitle":168,"status":124,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":173,"conditions":174,"interventions":175},"NCT01788072","INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders",[47],"2017-08","2017-10","2014-06",70,[15],[149],{"trials":177,"activeCount":56},[],{"trials":179,"activeCount":56},[],{"trials":181,"activeCount":56},[],{"intervention":183,"totalTrials":9,"cells":184},"Arbaclofen",{"EARLY_PHASE1":185,"PHASE1":187,"PHASE2":189,"PHASE3":200,"PHASE4":202,"NA":204},{"trials":186,"activeCount":56},[],{"trials":188,"activeCount":56},[],{"trials":190,"activeCount":56},[191],{"nctId":192,"briefTitle":193,"status":124,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT03887676","Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)",[47],"2023-08-04","2019-03-18",90,[15],[183],{"trials":201,"activeCount":56},[],{"trials":203,"activeCount":56},[],{"trials":205,"activeCount":56},[],{"intervention":207,"totalTrials":9,"cells":208},"Riluzole",{"EARLY_PHASE1":209,"PHASE1":211,"PHASE2":213,"PHASE3":223,"PHASE4":225,"NA":227},{"trials":210,"activeCount":56},[],{"trials":212,"activeCount":56},[],{"trials":214,"activeCount":56},[215],{"nctId":216,"briefTitle":217,"status":124,"phases":218,"primaryCompletion":161,"completion":138,"start":163,"enrollment":219,"conditions":220,"interventions":222},"NCT01661855","A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD",[47],58,[221],"Autism Spectrum Disorders",[207],{"trials":224,"activeCount":56},[],{"trials":226,"activeCount":56},[],{"trials":228,"activeCount":56},[],{"intervention":230,"totalTrials":9,"cells":231},"Tideglusib",{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":233,"activeCount":56},[],{"trials":235,"activeCount":56},[],{"trials":237,"activeCount":56},[238],{"nctId":239,"briefTitle":240,"status":124,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":246},"NCT02586935","Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders",[47],"2018-02-25","2016-02-10",83,[221],[230],{"trials":248,"activeCount":56},[],{"trials":250,"activeCount":56},[],{"trials":252,"activeCount":56},[],{"intervention":254,"totalTrials":9,"cells":255},"Fluoxetine",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":257,"activeCount":56},[],{"trials":259,"activeCount":56},[],{"trials":261,"activeCount":56},[],{"trials":263,"activeCount":56},[],{"trials":265,"activeCount":56},[],{"trials":267,"activeCount":56},[268],{"nctId":269,"briefTitle":270,"status":124,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":9,"conditions":274,"interventions":278},"NCT06341127","Fluoxetine in KCNC1-related Disorder",[50],"2024-11-28","2024-01-17",[275,276,277],"KCNC1 Related Disorder","Genetic Disease","Rare Diseases",[254]]